부산대학교 도서관

The clinical effects and safety of imipenem/cilastatin sodium (MK-0787/MK-0791), a new carbapenem antibiotic, were studied in 13 patients with respiratory tract infections.MK-0787/MK-0791 was injected intravenously by drip infusion in a daily dose of 750mg/750mg to 2000mg/2000mg for 6 to 35 days. The maximum total dose administered was 46g/46g.The thirteen patients consisted of 9 with pneumonia, 2 with pulmonary abscess and 2 cases of bronchiectasis with infection.Excellent results were obtained in 7 patients, good in 6 and fair in 1. The overall efficacy rate was 92.3%.Post-treatment laboratory findings showed elevation of S-GOT, S-GPT and Al-P in 1 patient, pancytopenia in 1 patient and leukopenia in 1 patient.No subjective side effect was observed in any patient.